Background: Epstein–Barr virus (EBV) infection is common in childhood and frequently accompanied by liver enzyme abnormalities. Although hepatic involvement is generally self-limited, pediatric data on predictors of hepatitis and biochemical recovery dynamics remain limited. This study aimed to evaluate the frequency and severity of hepatic involvement in children with primary EBV infection and identify clinical and laboratory features associated with hepatitis. Methods: This retrospective cohort study included children aged 0–18 years with serologically confirmed primary EBV infection at a tertiary center between January 2015 and November 2024. Patients with cytomegalovirus co-infection, hepatotropic viral infections, chronic liver disease, hepatotoxic drug exposure, or incomplete records were excluded. Demographic, clinical, and laboratory data were collected. Hepatic involvement was defined as ALT elevation above age-adjusted upper limits. Group comparisons utilized appropriate parametric and non-parametric tests, and logistic regression assessed predictors of hepatitis. Results: A total of 294 patients were included (median age: 6.1 years), of whom 48.6% were male. Hepatitis occurred in 59.2% of cases. Children with hepatitis were older than those without (median 6.7 vs. 5.3 years, p < 0.001). Logistic regression demonstrated that increasing age independently predicted hepatitis (odds ratio per year increase: 1.010; 95%CI 1.005–1.015; p < 0.001). Median time to ALT normalization was 20 days, and no patient developed acute liver failure. Conclusions: Hepatic involvement is common in pediatric EBV infection and is more frequent in older children. Despite significant biochemical abnormalities, all patients recovered fully with supportive care. Recognizing age-related risk and typical recovery patterns may reduce unnecessary investigations and guide appropriate management in pediatric EBV hepatitis.
The gastrointestinal system communicates with the brain by way of vagus nerve fibers and the gut-brain axis. There is a well-known relationship between autoimmune diseases and epileptogenesis, and this may explain the involvement of gut microbiota in the course of epilepsy. Many seizures which are described, depending the severity and/or duration, as benign or epilepsy may be related and based on gastrointestinal origin. Epilepsy and related neurological symptoms may alert the clinician to additional life-threatening conditions and complications during the course of gastrointestinal system-based chronic disease such as inflammatory bowel disease and celiac disease. Since the gut is the only part of inner body exposed to environment, novel therapeutic options that target gut microbiata may be promising in many diseases including epilepsy.
Tumor necrosis factor-alpha (TNF-α) has an important role in hypoxia/reoxygenation (H/R)-induced intestinal damage. It was shown that blocking TNF-α with infliximab has beneficial effects on experimental necrotizing enterocolitis and hypoxic intestinal injury. However, there is no data about the effect of adalimumab on H/R-induced intestinal damage. Therefore, we aimed to determine potential dose-dependent benefits of adalimumab in such damage in neonatal rats. Wistar albino rat pups were assigned to one of the four groups: control group, hypoxia group, low-dose adalimumab (5 mg/kg/day) treated group (LDAT), and high-dose adalimumab (50 mg/kg/day) treated group (HDAT). On the fourth day of the experiment, all rats except for the control group were exposed to H/R followed by euthanasia. Malondialdehyde (MDA), myeloperoxidase (MPO), TNF-α, total antioxidant capacity (TAC), and total oxidant capacity (TOC) were measured in intestinal tissue. TAC and TOC values were used to calculate the oxidative stress index (OSI). Histopathological injury scores (HIS) were also evaluated in the tissue samples. MDA levels were significantly lower in the LDAT and HDAT groups (p < 0.001). TNF-α levels were significantly lower in the LDAT group (p < 0.001). OSI was significantly higher in the H/R group than in the control and LDAT groups (p < 0.001). Mean HIS values in the LDAT group were significantly lower than those in the H/R and HDAT groups (p < 0.001). This experimental study showed that low-dose adalimumab appears to have a beneficial effect on intestinal injury induced with H/R in neonatal rats.
30 November 2018 in ARCHIVES OF CLINICAL AND EXPERIMENTAL MEDICINE
Aim: To investigate the prevalence of celiac disease (CD) among children with Down’s syndrome (DS) and its association with gastrointestinal symptoms and other accompanying diseases. Methods: The study was consisted of regular trisomy 21 patients who were under follow-up in our department. The age, gender, gastrointestinal symptoms (abdominal pain, constipation, diarrhea, abdominal distension, vomiting, flatulence, and unsatisfactory weight gain/weight loss) and accompanying diseases were recorded. Anti-tissue transglutaminase (anti-tTG) immunoglobulin A (Ig A) levels were analyzed in all cases. Serologically positive patients were referred to a pediatric gastroenterologist for intestinal biopsy. Results: Totally 98 children with a mean age of 3.2±2.81 years (range: 2-13 years) diagnosed with the DS were included in this study. Among study participants, 46 (46.9%) were female. Among study participants, 3 (3.1%) had positive anti-tTG IgA results and endoscopic biopsies revealed the diagnosis of Marsh type 3b CD in all of them. In correlation analysis, hypothyroidism (p=0.03) and presence of diarrhea (p=0.04) significantly correlated with the CD presence among children with the DS. Diarrhea increased the risk for 1.50 times (0.67-3.34) while hypothyroidism increased the risk for 2.75 times (0.55-13.67) among patients with DS. Conclusion: Clinicians should be aware of an increased prevalence of CD among patients with DS especially in children with diarrhea and/or hypothyroidism.